← Back to Clinical Trials
Recruiting NCT07717554

NCT07717554 Effect of Virtual Yoga in Diabetic Gastroparesis Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07717554
Status Recruiting
Phase
Sponsor Ohio State University
Condition Diabetic Gastroparesis
Study Type INTERVENTIONAL
Enrollment 240 participants
Start Date 2026-07-17
Primary Completion 2028-07-16

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Virtual Yoga

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 240 participants in total. It began in 2026-07-17 with a primary completion date of 2028-07-16.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to investigate the potential benefits of an online yoga module for patients with gastroparesis. Specifically, the study aims to: 1. Evaluate the Impact of Yoga Practices: Examine whether practicing yoga, including pranayama (breathing techniques), mindfulness meditation, and guided relaxation, can help reduce symptoms of gastroparesis, such as nausea, vomiting, bloating, and abdominal pain. 2. Assess Psychological Factors: Determine if the yoga intervention can improve associated psychological factors, including mental well-being, sleep quality, and overall quality of life for individuals with gastroparesis. 3. Provide Evidence-Based Insights: Contribute to the evidence base on the effectiveness of non-pharmacological treatments like yoga in managing gastroparesis, which may offer an additional, accessible management option for patients.

Eligibility Criteria

Inclusion Criteria: * History of type 1 or type 2 diabetes Gastroparesis defined by documented delayed gastric emptying, assessed by a 4-hour gastric emptying test showing more than 10% retained food in the stomach after 4 hours. This test must have been performed clinically before study enrolment. * Experiencing at least moderate Gastroparesis symptoms Exclusion Criteria: * Patients with severe depression or severe anxiety as assessed by screening questionnaire. Patients with Active inflammatory bowel disease. Participants with abdominal surgeries within the last 3 months. Severe Co-morbidities: Presence of severe comorbid conditions (e.g., advanced cardiovascular or respiratory disease) that could interfere with participation in the yoga intervention. Patients who self-report with current Pregnancy and Breastfeeding * Regular yoga practitioners (more than once a week) in the last 6 months. Undergoing current treatment for any cancer.

Contact & Investigator

Central Contact

SUBHANKAR CHAKRABORTY, M.D., Ph.D.

✉ Subhankar.chakraborty@osumc.edu

📞 614-293-6255'

Principal Investigator

Subhankar CHAKRABORTY, MD, Ph.D.

PRINCIPAL INVESTIGATOR

Ohio State University

Frequently Asked Questions

Who can join the NCT07717554 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Diabetic Gastroparesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07717554 currently recruiting?

Yes, NCT07717554 is actively recruiting participants. Contact the research team at Subhankar.chakraborty@osumc.edu for enrollment information.

Where is the NCT07717554 trial being conducted?

This trial is being conducted at Columbus, United States.

Who is sponsoring the NCT07717554 clinical trial?

NCT07717554 is sponsored by Ohio State University. The principal investigator is Subhankar CHAKRABORTY, MD, Ph.D. at Ohio State University. The trial plans to enroll 240 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology